^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Campath (alemtuzumab)

    i
    Other names: LDP 03, Campath-1H, LDP-03, MoAb CD52, monoclonal antibody Campath-1H, CLLS52, CLLS-52, LDP03, CLLS 52
    Company:
    Bayer, Sanofi
    Drug class:
    CD52 inhibitor
    Related drugs:
    9d
    T-PLL: Observatory of Prolymphocytic Leukemia T (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab)
    16d
    Asymptomatic T prolymphocytic leukemia: case report and literature review. (PubMed, Einstein (Sao Paulo))
    Standard therapies include alemtuzumab-based regimens and hematopoietic stem cell transplantation, although relapse rates remain high. This case underscores the need to recognize indolent presentations of T-cell prolymphocytic leukemia that may be managed conservatively. Further research is required to identify prognostic markers and optimize therapeutic strategies.
    Review • Journal
    |
    ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ATM mutation
    |
    Campath (alemtuzumab)
    24d
    Islet Cell Transplant for Type 1 Diabetes (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab)
    1m
    Excellent outcome of one-day non-myeloablative salvage regimen for paediatric patients with graft failure following haploidentical haematopoietic stem cell transplantation. (PubMed, Transplant Cell Ther)
    To conclude, local experience suggested that the modified 1-day reduced-intensity regimen in combination with fresh but not cryopreserved PBSC graft is feasible and promising to achieve sustained engraftment. It is a safe and appropriate approach in salvaging paediatric patients with graft failure requiring immediate re-transplantation.
    Journal
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • fludarabine IV
    2ms
    Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients (clinicaltrials.gov)
    P=N/A, N=20, Completed, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion • Trial completion date
    |
    Campath (alemtuzumab) • hydroxyurea
    3ms
    A Rare Case of Renal Failure Caused by T-Cell Prolymphocytic Leukaemia Infiltration. (PubMed, Case Rep Hematol)
    He required haemodialysis, but was treated with pulsed methylprednisolone and alemtuzumab, with excellent renal recovery, although remission was not achieved. This case demonstrates that renal leukaemic infiltration must be considered in T-PLL patients with rapidly progressive renal failure, and that solid organ invasion should not contraindicate timely commencement of T-PLL-directed therapy with alemtuzumab.
    Journal
    |
    STAT5B (Signal Transducer And Activator Of Transcription 5B)
    |
    Campath (alemtuzumab)
    3ms
    NatHaLi-01: Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Cellectis S.A. | Trial completion date: Nov 2027 --> Aug 2027 | Trial primary completion date: Nov 2027 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
    |
    CD20 positive
    |
    Campath (alemtuzumab) • etivelcabtagene erigedleucel (UCART20x22)
    4ms
    Reduced Intensity Transplantation for Severe Sickle Cell Disease (clinicaltrials.gov)
    P2, N=40, Suspended, St. Jude Children's Research Hospital | Trial completion date: Aug 2027 --> Aug 2029
    Trial completion date
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • hydroxyurea • thiotepa • plerixafor
    4ms
    HLA-Identical Sibling Renal Transplant Tolerance (clinicaltrials.gov)
    P=N/A, N=88, Completed, Northwestern University | Active, not recruiting --> Completed
    Trial completion
    |
    Campath (alemtuzumab) • sirolimus
    4ms
    AMELI-01: Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Cellectis S.A. | Recruiting --> Active, not recruiting | N=65 --> 29 | Trial completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Campath (alemtuzumab) • UCART123
    4ms
    Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (clinicaltrials.gov)
    P1/2, N=1, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    CD40LG (CD40 ligand)
    |
    Campath (alemtuzumab) • sirolimus • busulfan • Kepivance (palifermin)
    5ms
    Real-world safety and effectiveness of alemtuzumab as a conditioning regimen for hematopoietic stem cell transplantation. (PubMed, Int J Hematol)
    Engraftment was achieved in 55 of 58 patients (94.8%) at a median of 16 days after HSCT, and predefined success (engraftment without grade ≥ 3 graft-versus-host disease in hematologic malignancies or grade ≥ 2 in other diseases) was met in 51 of 58 patients (87.9%). These results support the manageable safety profile and effectiveness of alemtuzumab as preconditioning for HSCT in Japanese patients.
    Journal • Real-world evidence
    |
    CD52 (CD52 Molecule)
    |
    Campath (alemtuzumab)